Anti-TNF and postoperative complications in abdominal crohn's disease surgery
Main Author: | |
---|---|
Publication Date: | 2019 |
Other Authors: | , , , |
Format: | Other |
Language: | eng |
Source: | Repositório Institucional da UNESP |
Download full: | http://dx.doi.org/10.2174/1389450120666190404144048 http://hdl.handle.net/11449/201197 |
Summary: | Background: Biological therapy with anti-Tumour Necrosis Factor (TNF)-α agents revolutionised the treatment of inflammatory bowel disease over the last decades. However, there may be an increased risk of postoperative complications in Crohn’s disease (CD) patients treated with anti-TNF-α agents prior to abdominal surgery. Objective: To evaluate the effects of preoperative anti-TNF-α therapy on the incidence of complications after surgery. Methods: A critical assessment of the results of clinical trial outcomes and meta-analyses on the available data was conducted. Results: Based on the outcomes of previous reports including meta-analyses, preoperative use of anti-TNF-α agents modestly increased the risk of overall complications and particularly infectious complications after abdominal surgery for CD. Nevertheless, previous studies have several limitations. The majority of them were retrospective research with heterogeneous outcome measures and single centre trials with relatively small sample size. In retrospective studies, the standard protocol for assessing various types of postoperative complications was not used. The most serious limitation of the previous studies was that multiple confounding factors such as malnutrition, use of corticosteroids, and preoperative sepsis were not taken into consideration. Conclusion: Among patients treated with preoperative anti-TNF-α therapy, the risk of overall complications and infectious complications may slightly increase after abdominal surgery for CD. Nevertheless, the previous reports reviewed in this study suffered from limitations. To rigorously evaluate the risk of anti-TNF-α therapy prior to surgery, large prospective studies with standardised criteria for assessing surgical complications and with proper adjustment for confounding variables are warranted. |
id |
UNSP_1283e31cfb69b37a97cb04d9c9c58cb9 |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/201197 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
Anti-TNF and postoperative complications in abdominal crohn's disease surgeryAnastomotic complicationsAnti-TNF agentsAnti-tumour necrosis factor-alpha agentsBiologicsCrohn’s diseaseInfectious complicationsPostoperative complicationsSurgeryBackground: Biological therapy with anti-Tumour Necrosis Factor (TNF)-α agents revolutionised the treatment of inflammatory bowel disease over the last decades. However, there may be an increased risk of postoperative complications in Crohn’s disease (CD) patients treated with anti-TNF-α agents prior to abdominal surgery. Objective: To evaluate the effects of preoperative anti-TNF-α therapy on the incidence of complications after surgery. Methods: A critical assessment of the results of clinical trial outcomes and meta-analyses on the available data was conducted. Results: Based on the outcomes of previous reports including meta-analyses, preoperative use of anti-TNF-α agents modestly increased the risk of overall complications and particularly infectious complications after abdominal surgery for CD. Nevertheless, previous studies have several limitations. The majority of them were retrospective research with heterogeneous outcome measures and single centre trials with relatively small sample size. In retrospective studies, the standard protocol for assessing various types of postoperative complications was not used. The most serious limitation of the previous studies was that multiple confounding factors such as malnutrition, use of corticosteroids, and preoperative sepsis were not taken into consideration. Conclusion: Among patients treated with preoperative anti-TNF-α therapy, the risk of overall complications and infectious complications may slightly increase after abdominal surgery for CD. Nevertheless, the previous reports reviewed in this study suffered from limitations. To rigorously evaluate the risk of anti-TNF-α therapy prior to surgery, large prospective studies with standardised criteria for assessing surgical complications and with proper adjustment for confounding variables are warranted.Department of Surgery and IBD Centre Yokkaichi Hazu Medical CentreDepartment of Colorectal Surgery Gastrosaude ClinicDigestive Surgery Department São Paulo State University (UNESP)Colorectal Surgery Unit Catholic University of Paraná (PUCPR)IBD Centre Department of Gastroenterology Humanitas Clinical and Research CentreDigestive Surgery Department São Paulo State University (UNESP)Yokkaichi Hazu Medical CentreGastrosaude ClinicUniversidade Estadual Paulista (Unesp)Catholic University of Paraná (PUCPR)Humanitas Clinical and Research CentreYamamoto, TakayukiTeixeira, Fabio VieiraSaad-Hossne, Rogerio [UNESP]Kotze, Paulo GustavoDanese, Silvio2020-12-12T02:26:32Z2020-12-12T02:26:32Z2019-01-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/other1339-1348http://dx.doi.org/10.2174/1389450120666190404144048Current Drug Targets, v. 20, n. 13, p. 1339-1348, 2019.1873-55921389-4501http://hdl.handle.net/11449/20119710.2174/13894501206661904041440482-s2.0-85072686975Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengCurrent Drug Targetsinfo:eu-repo/semantics/openAccess2024-08-14T14:19:56Zoai:repositorio.unesp.br:11449/201197Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestrepositoriounesp@unesp.bropendoar:29462024-08-14T14:19:56Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
Anti-TNF and postoperative complications in abdominal crohn's disease surgery |
title |
Anti-TNF and postoperative complications in abdominal crohn's disease surgery |
spellingShingle |
Anti-TNF and postoperative complications in abdominal crohn's disease surgery Yamamoto, Takayuki Anastomotic complications Anti-TNF agents Anti-tumour necrosis factor-alpha agents Biologics Crohn’s disease Infectious complications Postoperative complications Surgery |
title_short |
Anti-TNF and postoperative complications in abdominal crohn's disease surgery |
title_full |
Anti-TNF and postoperative complications in abdominal crohn's disease surgery |
title_fullStr |
Anti-TNF and postoperative complications in abdominal crohn's disease surgery |
title_full_unstemmed |
Anti-TNF and postoperative complications in abdominal crohn's disease surgery |
title_sort |
Anti-TNF and postoperative complications in abdominal crohn's disease surgery |
author |
Yamamoto, Takayuki |
author_facet |
Yamamoto, Takayuki Teixeira, Fabio Vieira Saad-Hossne, Rogerio [UNESP] Kotze, Paulo Gustavo Danese, Silvio |
author_role |
author |
author2 |
Teixeira, Fabio Vieira Saad-Hossne, Rogerio [UNESP] Kotze, Paulo Gustavo Danese, Silvio |
author2_role |
author author author author |
dc.contributor.none.fl_str_mv |
Yokkaichi Hazu Medical Centre Gastrosaude Clinic Universidade Estadual Paulista (Unesp) Catholic University of Paraná (PUCPR) Humanitas Clinical and Research Centre |
dc.contributor.author.fl_str_mv |
Yamamoto, Takayuki Teixeira, Fabio Vieira Saad-Hossne, Rogerio [UNESP] Kotze, Paulo Gustavo Danese, Silvio |
dc.subject.por.fl_str_mv |
Anastomotic complications Anti-TNF agents Anti-tumour necrosis factor-alpha agents Biologics Crohn’s disease Infectious complications Postoperative complications Surgery |
topic |
Anastomotic complications Anti-TNF agents Anti-tumour necrosis factor-alpha agents Biologics Crohn’s disease Infectious complications Postoperative complications Surgery |
description |
Background: Biological therapy with anti-Tumour Necrosis Factor (TNF)-α agents revolutionised the treatment of inflammatory bowel disease over the last decades. However, there may be an increased risk of postoperative complications in Crohn’s disease (CD) patients treated with anti-TNF-α agents prior to abdominal surgery. Objective: To evaluate the effects of preoperative anti-TNF-α therapy on the incidence of complications after surgery. Methods: A critical assessment of the results of clinical trial outcomes and meta-analyses on the available data was conducted. Results: Based on the outcomes of previous reports including meta-analyses, preoperative use of anti-TNF-α agents modestly increased the risk of overall complications and particularly infectious complications after abdominal surgery for CD. Nevertheless, previous studies have several limitations. The majority of them were retrospective research with heterogeneous outcome measures and single centre trials with relatively small sample size. In retrospective studies, the standard protocol for assessing various types of postoperative complications was not used. The most serious limitation of the previous studies was that multiple confounding factors such as malnutrition, use of corticosteroids, and preoperative sepsis were not taken into consideration. Conclusion: Among patients treated with preoperative anti-TNF-α therapy, the risk of overall complications and infectious complications may slightly increase after abdominal surgery for CD. Nevertheless, the previous reports reviewed in this study suffered from limitations. To rigorously evaluate the risk of anti-TNF-α therapy prior to surgery, large prospective studies with standardised criteria for assessing surgical complications and with proper adjustment for confounding variables are warranted. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-01-01 2020-12-12T02:26:32Z 2020-12-12T02:26:32Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/other |
format |
other |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.2174/1389450120666190404144048 Current Drug Targets, v. 20, n. 13, p. 1339-1348, 2019. 1873-5592 1389-4501 http://hdl.handle.net/11449/201197 10.2174/1389450120666190404144048 2-s2.0-85072686975 |
url |
http://dx.doi.org/10.2174/1389450120666190404144048 http://hdl.handle.net/11449/201197 |
identifier_str_mv |
Current Drug Targets, v. 20, n. 13, p. 1339-1348, 2019. 1873-5592 1389-4501 10.2174/1389450120666190404144048 2-s2.0-85072686975 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Current Drug Targets |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
1339-1348 |
dc.source.none.fl_str_mv |
Scopus reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
repositoriounesp@unesp.br |
_version_ |
1834483699621560320 |